FedEx came up short on top and bottom lines, and guidance revisions suggest there is more bad news to come in fiscal 2025.

There's nothing like a potentially massive government contract to win the hearts of both investors and analysts.

The biotech had discouraging news to report about one of its pipeline drugs. The FDA declined to approve its application. Bad ...

The stock market is on fire on Thursday and that has extended to cryptocurrencies as well. Over the past 24 hours, the value ...

While the broad stock market was soaring on interest rate cuts today, Skechers ( SKX -9.62%), the casual footwear specialist, was moving in the opposite direction, tumbling after it told investors ...

That news is behind the surprising strength in shares of Intel stock (up 3% through 11:10 a.m. ET), and in Alphabet (up 1.8%) ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Shares of Progyny ( PGNY -29.62%) were crashing 30.1% lower as of 11:22 a.m. ET on Thursday. The steep decline came after the ...

Carnival's guidance back in June was revised higher. It now expects to earn $1.18 a share for this fiscal year, which ends in ...

Shares of biopharma outfit Edgewise Therapeutics ( EWTX 47.93%) soared more than 50% today, reaching a three-year high ...

While investors are happy about the decision, Fed Chair Jerome Powell said the Fed is not yet calling victory on inflation.

Argan may be that rarest of beasts: a dividend stock that's also a value and growth-at-a-reasonable-price (GARP) stock.